BPI-9016M

Cat. No.: HY-114356

CAS No.: 1528546-94-2

Molecular Formula: $C_{25}H_{18}F_2N_4O_3$

Molecular Weight: 460.43

Target: c-Met/HGFR

Pathway: Protein Tyrosine Kinase/RTK

Storage: 4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (217.19 mM; Need ultrasonic)

Preparing Stock Solutions	Concentration \ Solvent \ Mass	1 mg	5 mg	10 mg
	1 mM	2.1719 mL	10.8594 mL	21.7188 mL
	5 mM	0.4344 mL	2.1719 mL	4.3438 mL
	10 mM	0.2172 mL	1.0859 mL	2.1719 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma[1][2].

In Vitro

BPI-9016M (6.3-25 μM; 2 weeks) inhibited cell proliferation[2].
BPI-9016M (12.5-50 μM; 24 hpurs) induces accumulation of more tumor cells in the G1 phase[2].
BPI-9016M (3.1-50 μM) reduces expression of c-Met, p-c-Met, p-AKT and p-ERK in the H1299 and A549 cells in a dose-dependent manner[2].
The IC_{50} of BPI-9016M in several lung adenocarcinoma cell lines (A549, H1299, H1650, H1975, HCC827, and PC-9 cells) as well as in primary lung adenocarcinoma cells are ranged from 5.3 μM to 27.1 μM[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[2]

Cell Line:	A549 and H1299 cells
Concentration:	6.3, 12.5, 25 μM

Incubation Time:	2 weeks
Result:	Colony formation was significantly inhibited in a dose-dependent manner.

Cell Cycle Analysis[2]

Cell Line:	A549 and H1299 cells
Concentration:	12.5, 25, 50 μM
Incubation Time:	24 hours
Result:	Induced accumulation of more tumor cells in the G1 phase.

In Vivo

BPI-9016M (60 mg/kg; p.o.; daily for 16 or 12 days) dramatically restrains tumor growth in PDX xenografts in NOD/SCID mice [2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID mice[2]
Dosage:	60 mg/kg
Administration:	p.o.; daily for 16 or 12 days
Result:	Dramatically restrained tumor growth in PDX xenografts in NOD/SCID mice.

REFERENCES

[1]. Zhang P, et al. BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1. Theranostics. 2018 Nov 12;8(21):5890-5902.

[2]. Hu X, et al. First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer.J Hematol Oncol. 2020 Jan 16;13(1):6.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA